Evidence map›Paper›PMID 32775300›Full record

ArticleFrontiers in oncology2020

PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR.

Jinqi Lv, Tianshu Guo, Xiujuan Qu, Xiaofang Che, Ce Li, Shuo Wang, Jing Gong, Peihong Wu, Yang Liu, Yunpeng Liu and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy.Frontiers in molecular biosciences · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Jinqi LvDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Tianshu GuoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiujuan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiaofang CheDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Ce LiDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Shuo WangDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Jing GongDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Peihong WuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Yang LiuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Yunpeng LiuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Ling XuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
First Hospital of China Medical University · CNMinistry of Education of the People's Republic of China · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has received extensive attention as a cancer therapeutic due to its high propensity for tumor targeting with minimal toxicity to healthy tissue. Gastric cancer (GCa) cells show high levels of TRAIL resistance. Epidermal growth factor receptor (EGFR) antagonizes TRAIL-induced apoptosis, but the mechanisms of these effects remain unclear. Our past research confirmed TRAIL-resistant (BGC823 and SGC7901) and TRAIL-sensitive cells (HGC27 and MKN45). miR-429 associated with TRAIL sensitivity was screened using microRNA arrays. The transfection of mimics and inhibitors confirmed that miR-429 negatively correlated with GCa TRAIL resistance. The target gene of miR-429 was identified as PD-L1, which positively correlated with TRAIL resistance through gene silencing and recovery experiments. Using co-immunoprecipitation (co-IP) and proximity ligation assay, we demonstrated that the pro-survival effects of PD-L1 are mediated through the binding and activation of EGFR. Cell viability experiments demonstrated that PD-L1 is key to the maintenance of cell viability in TRAIL-treated cells. This indicated that PD-L1 binds to and participates in EGFR activation through miR-429 regulation to antagonize TRAIL-induced apoptosis. This provides a new theoretical basis for the combination of the EGFR monoclonal antibodies including cetuximab, PD-L1 inhibitors, and human recombinant TRAIL in gastric cancer therapy and can filter patients who are currently sensitive to TRAIL treatment.

Indexed as

EGFRgastric cancermiR-429PD-L1TRAIL

Identifiers

PMID32775300
PMCPMC7387728
OpenAlexW3044884245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.